China’s Wangli Technology Secures Funding for AI-Powered Digital Mental Health Platform
Wangli Technology, a Chinese digital mental health diagnosis and therapy platform, has completed a Series B+ funding round, raising several million yuan led by Yuan Yi Capital. The company is as well initiating a new round of financing with Index Capital serving as its financial advisor. This investment will primarily fuel product development and expansion of its services.
Leveraging Data and AI for Mental Healthcare
Wangli Technology differentiates itself through its extensive database of 300,000 real patient data points and a commitment to research, having published over ten articles in leading international psychiatry journals and undertaken several national research projects. The platform offers a comprehensive solution combining professional equipment, a mobile application, and qualified mental health professionals.
WonderLab: An AI-Driven Therapy Optimization System
At the core of Wangli Technology’s innovation is WonderLab, a large-scale model powered by artificial intelligence. According to Li Dai, founder and CEO, WonderLab integrates various psychological therapy approaches, including Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Psychodynamic Psychotherapy (PPT), and Cognitive Behavioral Modification (CBM), alongside cognitive training patterns. The system utilizes Reinforcement Learning (RL) and Just-in-Time Adaptive Intervention (JITAI) to optimize therapy delivery.
WonderLab employs a three-stage recommendation mechanism – macro, meso, and micro – to dynamically adjust intervention paths based on real-time detection of a user’s state changes. This allows for precise selection of optimal intervention tasks from a vast pool of options, delivering personalized care to each patient.
First Class III Approval for Digital Depression Treatment in China
In December 2025, Wangli Technology achieved a significant milestone with the Class III medical device approval of its antidepressant product, “Software for the Supportive Treatment of Depressive Symptoms” (Wangli Nuanyang WL-iCBT). This marks the first instance of a digital medical device receiving Class III approval in China for the treatment of depression and other mental and neurological disorders.
Wangli Nuanyang is built on mobile internet technology, large data analytics, and customized algorithms, incorporating evidence-based multimodal cognitive behavioral therapy and training to enhance cognitive function. Its dynamic adjustment of training and therapy levels, coupled with its accessibility, aims to better meet patient needs.
Rigorous Clinical Trials and Regulatory Approval
Class III medical device approval in China requires rigorous clinical trials with large sample sizes to demonstrate efficacy and safety. The pivotal trial for Wangli Nuanyang was led by the National Center for Psychiatry, involving a total of 11 hospitals nationwide. Assessments included antidepressant efficacy, safety, treatment adherence, anxiety levels, and cognitive function.
Wangli Technology prioritized the accuracy of clinical trial data, implementing stringent patient recruitment criteria and requiring unanimous evaluation by two doctors to ensure data integrity and minimize potential biases from concurrent diagnoses or medications.
Integration into National Guidelines and Reimbursement
Wangli Nuanyang is now recommended as a 1A-class treatment method in the 2025 edition of the “Chinese Guideline for the Prevention and Treatment of Depression” and is eligible for special reimbursement in hospitals, paving the way for broader commercial adoption.
Despite its recent approval, the platform has already garnered high patient acceptance and hospital interest due to its innovative therapeutic approaches and convenient accessibility.